Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials
- 31 August 2010
- journal article
- review article
- Published by Elsevier BV in Current Therapeutic Research
- Vol. 71 (4), 211-238
- https://doi.org/10.1016/j.curtheres.2010.08.003
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Exenatide compared with long‐acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long‐Acting insulin (HEELA) studyDiabetes, Obesity and Metabolism, 2009
- Taspoglutide: a long acting human glucagon-like polypeptide-1 analogueExpert Opinion on Investigational Drugs, 2009
- Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.International journal of clinical pharmacology and therapeutics, 2009
- Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2008
- Postprandial Hyperglycemia and Cardiovascular DiseaseEndocrine Practice, 2006
- Insulin Detemir—A New Basal Insulin AnalogAnnals of Pharmacotherapy, 2005
- Total Cholesterol and Mortality in China, Poland, Russia, and the USAnnals of Epidemiology, 2004
- The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetesDiabetologia, 2003
- Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO ConsultationDiabetic Medicine, 1998
- U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.1995